Annual Report to Security Holders (ars)

S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Annual Report to Security Holders (ars)

This regulatory filing also includes additional resources:
d453261dars.pdf

XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more XBiotech Charts.

XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more XBiotech Charts.

Xbiotech Inc. News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 10 May 2024 (6 days ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 7 February 2024 (3 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Wednesday 7 February 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 5 January 2024 (4 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
Thursday 4 January 2024 (4 months ago) • GlobeNewswire Inc.

Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
Tuesday 14 November 2023 (6 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 9 November 2023 (6 months ago) • Edgar (US Regulatory)

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Tuesday 26 September 2023 (8 months ago) • GlobeNewswire Inc.

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
Wednesday 30 August 2023 (9 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 11 August 2023 (9 months ago) • Edgar (US Regulatory)

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
Tuesday 8 August 2023 (9 months ago) • GlobeNewswire Inc.

More Xbiotech Inc. News Articles

Progressive Care (QB)

Faraday Future Intellige...

Greenwave Technology Sol...

Global Developments (PK)

Net Savings Link (PK)

Ronn Motor (PK)

Virexit Technologies (PK)

Clean Vision (QB)

Code Green Apparel (PK)

FBEC Worldwide (CE)

Yuenglings Ice Cream (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions